Trio Petroleum (TPET) : 18-month performance

Trio Petroleum Corp. operates as an oil and gas exploration and development company. 

• Sector: Energy
• Industry: Oil & Gas E&P
• Full Time Employees: 7
• Incorporated in 2021 
• Headquartered in Bakersfield, California
• https://trio-petroleum.com

ParaZero Technologies (PRZO) : 18-month performance

ParaZero Technologies Ltd. is an Israeli company that develops drone-based systems for logistics support. The company's HALO Precision Airdrop System is designed to deliver supplies in challenging environments. The Israeli Defense Export Controls Agency (DECA) approved the HALO system, which is intended to revolutionize drone-based logistical support. 

• Sector: Industrials
• Industry: Aerospace & Defense
• Full Time Employees: 14
• Founded by Amir Tsaliah and Ran Krauss in 2013
• Headquartered in Kiryat Ono, Israel
• https://parazero.com

IPO on July 26, 2023:  1,950,000 ordinary shares at a price to the public of $4.00 per share. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses, were $7.8 million.

Asset Entities (ASST) : 18-month performance

Asset Entities Inc., a technology company, provides social media marketing and content delivery services across Discord, TikTok, and other social media platforms. It designs, develops, and manages servers for communities on Discord. 

• Sector: Communication Services
• Industry: Internet Content & Information
• Full Time Employees: 11
• Founded in 2020 
• Based in Dallas, Texas
• https://www.assetentities.com

MicroCloud Hologram (HOLO) : 18-month performance

 MicroCloud Hologram Inc. is focused on holographic technology and quantum blockchain security.

• Sector: Technology
• Industry: Electronic Components
• Full Time Employees: 46
• Headquartered in Shenzhen, China
• https://www.mcholo.com

FTCI : 18-month performance

 ticker:  FTCI

G1 Therapeutics (GTHX) : placebo beats drug in cancer response rate test

G1 Therapeutics’ cancer drug trilaciclib has failed to beat placebo against multiple efficacy measures in phase 2. Trilaciclib performed well against its neutropenia-related primary endpoints but fell short in terms of response rate, prompting investors to send G1's stock down 26%.

   

death cross

North Carolina-based G1 designed the phase 2 to assess whether short-acting intravenous CDK4/6 inhibitor trilaciclib could reduce the occurrence and duration of Grade 4 neutropenia—a condition defined by abnormally low levels of a type of white blood cell—in patients with second or third-line small cell lung cancer (SCLC). The trial hit its primary endpoints by showing that trilaciclib, when added to chemotherapy drug topotecan, is more effective than placebo at controlling neutropenia.

That primary endpoint success enabled G1 to paint the results as positive. However, investors looked past the neutropenia data and zeroed in on a line deep in G1’s statement about rates of objective responses and clinical benefit seen in the trial, as well as the progression-free survival.

Of the 26 patients in the placebo arm, six responded, resulting in an objective response rate (ORR) of 23.1%. In the trilaciclib arm, four of the 30 patients responded, giving an ORR of 13.3%. The clinical benefit rate and progression-free survival were almost identical across the two arms, coming in at around 60% and 4.2 months, respectively.

G1 thinks trilaciclib may improve overall survival (OS) by preserving immune system function during chemotherapy. But G1 is yet to generate the mature OS data needed to validate that idea, and trilaciclib’s performance against other measures of efficacy has been mixed. A metastatic triple-negative breast cancer trial recently linked use of trilaciclib to improved ORR, but an earlier study in first-line SCLC found it was numerically worse than placebo against the objective response yardstick.

Despite that, G1 Chief Medical Officer Raj Malik thinks the biotech has emerged from the midphase program with data to support the advance of trilaciclib.

“We now have four randomized phase 2 trials showing trilaciclib’s multi-lineage myelopreservation benefits. We plan to meet with U.S. and European regulatory authorities in 2019 to discuss the totality of trilaciclib data and pathways to approval,” Malik said in a statement.

Blue Apron (APRN) drops below $1

• Blue Apron officially became a penny stock on Tuesday. Its shares closed down 11 pennies, to 90 cents, as the stock extended a long, steady post-IPO slide.
• The slide arguably started with the June 2017 IPO itself; at $10 a share, the deal priced lower than first anticipated.

Blue Apron’s (APRN) public experience gives investors something to contemplate as they look forward to a 2019 IPO lineup that could include big names like Uber, Lyft, Airbnb and Slack Technologies.

The company has been under attack on several fronts. Its subscription and delivery model offers appealing characteristics—and many who tried it loved it, or at least liked it—but acquiring and retaining customers proved to be a costly business for Blue Apron.

Those costs are even more problematic when you’re in a competitive industry—and Blue Apron certainly is, with companies such as HelloFresh (HFG.Germany), Albertson’s-owned Plated and Kroger -owned (KR) Home Chef—vying for many of same consumers and, often, doing so with comparable strategies.

In Blue Apron’s case, meanwhile, it’s not only dealing with an evolving meal-kit delivery business but also a fast-moving food industry in which grocery delivery is competing for some of those same dollars.

Is all lost for Blue Apron? In mid-November, with the shares in the neighborhood of a buck and a quarter, management announced a plan to get to profitability next year by focusing on their best customers, finding new sales channels, improving efficiency, and cutting staff.

Investors, for now, don’t seem to be giving the company much credit for that—though Wall Street’s average price target on the stock is near $1.60. Some degree of optimism may be associated with the possibility of a buyout by a company that likes the Blue Apron brand.

The biggest takeaway for IPO-minded investors might be a simple reminder that private valuations are far from a sure indicator of what the public markets might bear. In Blue Apron’s last private round, it was valued at about $2 billion. The company is worth less than a 10th of that now.

Mindbody (MB) reported earnings on Wed 26 Oct 2016 (a/h)

Ticker: MB

** charts after earnings **

 

SAN LUIS OBISPO, Calif. (AP) _ Mindbody Inc. (MB) on Wednesday reported a loss of $5.9 million in its third quarter.

On a per-share basis, the San Luis Obispo, California-based company said it had a loss of 15 cents. Losses, adjusted for stock option expense, were 9 cents per share.

The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 12 cents per share.

The business management software developer posted revenue of $35.3 million in the period, which also beat Street forecasts. Three analysts surveyed by Zacks expected $35 million.

For the current quarter ending in December, Mindbody said it expects revenue in the range of $37.7 million to $38.7 million.

The company expects full-year revenue in the range of $138.5 million to $139.5 million.

Mindbody shares have risen 18 percent since the beginning of the year. In the final minutes of trading on Wednesday, shares hit $17.90, a climb of 11 percent in the last 12 months.

Inovalon (INOV) reported earnings Wed 3 Aug 2016 (a/h)

** charts after earnings **

  

• Q2 revenue miss, and FY16 EPS and revenue guidance below consensus.

Second Quarter 2016 Highlights

• Second quarter revenue of $123.8 million
• Second quarter net income of $16.3 million, resulting in diluted net income of $0.11 per share
• Second quarter Non-GAAP net income of $20.6 million, resulting in Non-GAAP diluted net income of $0.14 per share
• Second quarter Adjusted EBITDA of $40.8 million
• MORE2 Registry® dataset medical event count expanded to more than 11.7 billion
• Accelerating transition to pure cloud-based platform and adjusting 2016 financial guidance

Synchrony Financial (SYF) reported 4Q earnings on Fri 22 Jan 2016 (b/o)

** charts before earnings **

  

** charts after earnings **

  

Synchrony Financial beats by $0.02  :

• Reports Q4 (Dec) earnings of $0.65 per share, $0.02 better than the Capital IQ Consensus of $0.63; platform revenues rose 4.8% year/year to $2.85 bln. 
• Return on assets was 2.6% and return on equity was 17.5%. Net interest margin increased 13 basis points to 15.73% due mainly to an improvement in interest-earning asset yields that resulted from carrying a higher mix of receivables versus lower-yielding liquidity.

Michaels Stores (MIK) reported earnings Thur 3 Dec 2015

** charts before earnings **

 ** charts after earnings **

Michaels Stores beats by $0.01, reports revs in-line; guides Q4 EPS :

• Reports Q3 (Oct) earnings of $0.37 per share, $0.01 better than the Capital IQ Consensus of $0.36; revenues rose 3.4% year/year to $1.17 bln vs the $1.17 bln Capital IQ Consensus. Comparable store sales increased by 1.5% or 3.1% on a constant currency basis.
• Co issues in-line guidance for Q4, sees EPS of $0.82-0.85 vs. $0.85 Capital IQ Consensus Estimate. Sees fourth quarter comparable store sales growth of 0.5% to 1.5% or 1.9% to 2.9% on a constant currency basis, operating income of $308 to $319 million.